Process Chemistry Approach to the Total Synthesis of BMS-813160

Seminar: Special Seminar | April 30 | 4-5 p.m. | 775 Tan Hall

 Dr. Michael Fenster, Bristol-Myers Squibb

 College of Chemistry

BMS-813160 is being investigated by Bristol-Myers Squibb as a combination therapy for colorectal and pancreatic cancer. In order to evaluate the clinical efficacy, a safe, robust, scalable, and cost-effective total synthesis was needed. The talk will focus on how process chemists enabled the production of multi-kg of BMS-813160 by route invention, process invention, and process characterization. This case study will describe the synthetic challenges and highlight the pertinent difficulties to executing reactions on scale.


 Dr. Michael Fenster CV